8-K: The Oncology Institute Announces $16.5 Million Private Placement

The Oncology Institute (TOI) has announced a private placement expected to generate $16.5 million in gross proceeds to support organic growth and working capital.

Summary

• The Oncology Institute, Inc. (TOI) has announced a private placement expected to result in gross proceeds of approximately $16.5 million before deducting fees and expenses.
• The private placement includes participation from existing investors, members of the company's management team, and the Board of Directors.
• The closing is expected on March 26, 2025, subject to customary closing conditions.
• The company will issue units consisting of two shares of common stock (or pre-funded warrants) and common warrants to purchase one share of common stock at $2.2084 per unit (or $2.2082 for units with pre-funded warrants).
• Pre-funded warrants have an exercise price of $0.0001 per share, while common warrants have an exercise price of $1.1980 per share.
• Investment funds affiliated with Deerfield Management Company, L.P. have entered into an exchange agreement to exchange approximately $4.1 million of senior secured convertible notes for common-equivalent preferred stock (convertible into 3,723,283 shares of Common Stock) and warrants to purchase 1,861,642 shares of common stock.
• The proceeds from the private placement will be used to support organic growth and working capital needs.
• BTIG is acting as the sole placement agent for the private placement.
• The securities have not been registered under the Securities Act of 1933 and are being offered in a private placement.
• TOI has agreed to file a resale registration statement with the SEC to register the resale of the common stock issued or issuable in connection with the private placement and the exchange agreement.

Sentiment

Score: 7

Explanation: The announcement is generally positive as it secures funding for the company's growth and working capital needs. However, the reliance on private placements and the potential need for a reverse stock split introduce some uncertainty.

Positives

• The private placement is expected to generate $16.5 million in gross proceeds.
• The proceeds will be used to support organic growth and working capital needs.
• Existing investors, management, and the Board of Directors are participating in the private placement, indicating confidence in the company.
• Deerfield Management Company, L.P. is exchanging $4.1 million of senior secured convertible notes for common-equivalent preferred stock and warrants, which could simplify the capital structure.
• TOI has agreed to file a resale registration statement with the SEC, providing liquidity for investors.

Negatives

• The securities have not been registered under the Securities Act of 1933 and are being offered in a private placement, limiting immediate liquidity.
• The company's reliance on private placements for funding may indicate challenges in accessing traditional capital markets.

Risks

• The forward-looking statements are subject to risks and uncertainties, including the outcome of judicial and administrative proceedings, changes in patient or payor preferences, and the impact of COVID-19.
• The company may face challenges in meeting stock exchange continued listing standards and may have to effect a reverse stock split.
• The securities have not been registered under the Securities Act of 1933 and are being offered in a private placement, limiting immediate liquidity.

Future Outlook

The company intends to use the proceeds from the private placement to support organic growth and working capital needs.

Industry Context

The Oncology Institute is one of the largest value-based community oncology groups in the United States, indicating a focus on delivering cost-effective cancer care in a community setting. The private placement and exchange agreement are part of the company's strategy to secure funding and manage its capital structure.

Related Party Transactions

• The private placement includes participation from members of the company's management team and Board of Directors.
• Investment funds affiliated with Deerfield Management Company, L.P., an existing investor in the Company, has entered into an exchange agreement.

Stakeholder Impact

• Shareholders: The private placement will dilute existing shareholders, but the proceeds are expected to support organic growth and working capital needs.
• Employees: The funding may provide greater job security and opportunities for advancement.
• Customers: The funding may allow the company to enhance its services and expand its reach.
• Creditors: The exchange agreement with Deerfield Management Company, L.P. may improve the company's financial stability.

Next Steps

• The company expects to close the private placement on March 26, 2025, subject to customary closing conditions.
• The company will file a resale registration statement with the SEC to register the resale of the common stock issued or issuable in connection with the private placement and the exchange agreement.

Key Dates

Keywords

private placement, warrants, common stock, Deerfield, Oncology Institute, registration rights, BTIG, securities, exchange agreement, preferred stock